SCHEMBL8353923

SCHEMBL8353923

CC(Nc1ccccc1N)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 3/20 0.54
▸ HDAC1 Q13547 3/20 0.54
▸ HDAC2 Q92769 3/20 0.54
▸ NCOR2 Q9Y618 3/20 0.54
▸ ALDH1A1 P00352 3/20 0.49
▸ KDM4E B2RXH2 3/20 0.49
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ NUDT1 P36639 1/20 0.46
▸ GAA P10253 2/20 0.45
▸ LMNA P02545 2/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ KDM4C Q9H3R0 1/20 0.44
▸ LDHA P00338 1/20 0.44
▸ LDHB P07195 1/20 0.44
▸ CRHBP P24387 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15722551 1.00 HDAC3 (0.54) HDAC3HDAC1HDAC2NCOR2ALDH1A1
SCHEMBL15722447 1.00 HDAC3 (0.54) HDAC3HDAC1HDAC2NCOR2ALDH1A1
SCHEMBL21427415 0.87 GAA (0.53) HDAC3HDAC1HDAC2NCOR2ALDH1A1
SCHEMBL18027646 0.85 MEN1 (0.53) ALDH1A1KDM4EMEN1KMT2ANUDT1
SCHEMBL28478972 0.84 MAPKAPK2 (0.46) HDAC3HDAC1HDAC2NCOR2ALDH1A1
SCHEMBL9193640 0.84 HDAC1 (0.65) HDAC3HDAC1HDAC2NCOR2ALDH1A1
SCHEMBL30894541 0.81 KDM4E (0.62) HDAC3HDAC1HDAC2NCOR2KDM4E
SCHEMBL15176894 0.79 CRHBP (0.43) ALDH1A1KDM4EMEN1KMT2ANUDT1
SCHEMBL14247790 0.79 L3MBTL1 (0.44) HDAC3HDAC1HDAC2NCOR2ALDH1A1
SCHEMBL14247727 0.79 L3MBTL1 (0.44) HDAC3HDAC1HDAC2NCOR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2925761-B1 TRIAZOLOPYRAZINES AS BRD4 INHIBITORS FOR USE IN THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INT (DE) 2017-07-05 — — EP disclosed
WO-2003002524-A2 UREA DERIVATIVES WITH ANTIPROTEOLYTIC ACTIVITY AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-01-09 — — WO disclosed
Send feedback